How to buy Cognition Therapeutics stock (Cognition Therapeutics)

Cognition Therapeutics is a biotechnology business based in the US. Cognition Therapeutics shares (CGTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.84 – an increase of 33.31% over the previous week. Cognition Therapeutics employs 25 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Cognition Therapeutics stock

Buy Cognition Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cognition Therapeutics stock price (NASDAQ: CGTX)

Use our graph to track the performance of CGTX stocks over time.

Cognition Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$0.84
52-week range	$0.34 - $2.95
50-day moving average more info button	$0.49
200-day moving average more info button	$1.22
Wall St. target price	$6.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.96

Is it a good time to buy Cognition Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cognition Therapeutics price performance over time

Historical closes compared with the close of $0.7674 from 2024-12-26

1 week (2024-12-20)	21.79%
1 month (2024-11-27)	92.86%
3 months (2024-09-27)	82.37%
6 months (2024-06-27)	-54.05%

1 year (2023-12-27)	-59.40%
2 years (2022-12-27)	-63.46%
3 years (2021-12-27)	6.25
5 years (2019-12-24)	N/A

Cognition Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-93.7%
Return on equity TTM	-108.31%
Profit margin	0%
Book value	$0.76
Market Capitalization more info button	$26.9 million

TTM: trailing 12 months

Cognition Therapeutics share dividends

We're not expecting Cognition Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Cognition Therapeutics share price volatility

Over the last 12 months, Cognition Therapeutics's shares have ranged in value from as little as $0.34 up to $2.95. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cognition Therapeutics's is 1.335. This would suggest that Cognition Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put Cognition Therapeutics's beta into context you can compare it against those of similar companies.

• BioNTech (BNTX.US): 0.259
• Novavax (NVAX.US): 2.088
• Regeneron Pharmaceuticals (REGN.US): 0.142

Cognition Therapeutics overview

Cognition Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York. .

Frequently asked questions

null
What percentage of Cognition Therapeutics is owned by insiders or institutions?
Currently 0.537% of Cognition Therapeutics shares are held by insiders and 24.534% by institutions. How many people work for Cognition Therapeutics?
Latest data suggests 25 work at Cognition Therapeutics. When does the fiscal year end for Cognition Therapeutics?
Cognition Therapeutics's fiscal year ends in December. Where is Cognition Therapeutics based?
Cognition Therapeutics's address is: 2500 Westchester Ave., Purchase, NY, United States, 10577 What is Cognition Therapeutics's ISIN number?
Cognition Therapeutics's international securities identification number is: US19243B1026